1 Department of Physiology, Pharmacology and Neuroscience, West Virginia School of Medicine, Morgantown, USA.
2 Department of Behavioral Medicine and Psychiatry, West Virginia School of Medicine, Morgantown, USA.
J Psychopharmacol. 2018 Feb;32(2):191-203. doi: 10.1177/0269881117742100. Epub 2018 Jan 24.
Regulators of G protein signaling are proteins that accelerate the termination of effector stimulation after G protein-coupled receptor activation. Many regulators of G protein signaling proteins are highly expressed in the brain and therefore considered potential drug discovery targets for central nervous system pathologies; for example, here we show that RGS12 is highly expressed in microdissected mouse ventral striatum. Given a role for the ventral striatum in psychostimulant-induced locomotor activity, we tested whether Rgs12 genetic ablation affected behavioral responses to amphetamine and cocaine. RGS12 loss significantly decreased hyperlocomotion to lower doses of both amphetamine and cocaine; however, other outcomes of administration (sensitization and conditioned place preference) were unaffected, suggesting that RGS12 does not function in support of the rewarding properties of these psychostimulants. To test whether observed response changes upon RGS12 loss were caused by changes to dopamine transporter expression and/or function, we prepared crude membranes from the brains of wild-type and RGS12-null mice and measured dopamine transporter-selective [H]WIN 35428 binding, revealing an increase in dopamine transporter levels in the ventral-but not dorsal-striatum of RGS12-null mice. To address dopamine transporter function, we prepared striatal synaptosomes and measured [H]dopamine uptake. Consistent with increased [H]WIN 35428 binding, dopamine transporter-specific [H]dopamine uptake in RGS12-null ventral striatal synaptosomes was found to be increased. Decreased amphetamine-induced locomotor activity and increased [H]WIN 35428 binding were recapitulated with an independent RGS12-null mouse strain. Thus, we propose that RGS12 regulates dopamine transporter expression and function in the ventral striatum, affecting amphetamine- and cocaine-induced increases in dopamine levels that specifically elicit acute hyperlocomotor responses.
G 蛋白信号转导调节剂是一类能够加速 G 蛋白偶联受体激活后效应器刺激终止的蛋白质。许多 G 蛋白信号转导调节剂在大脑中高度表达,因此被认为是中枢神经系统疾病潜在的药物发现靶点;例如,在这里我们表明 RGS12 在小鼠腹侧纹状体的微切割中高度表达。鉴于腹侧纹状体在精神兴奋剂诱导的运动活性中的作用,我们测试了 Rgs12 基因缺失是否会影响对安非他命和可卡因的行为反应。RGS12 缺失显著降低了对较低剂量安非他命和可卡因的过度运动;然而,其他给药结果(敏化和条件性位置偏好)不受影响,表明 RGS12 不支持这些精神兴奋剂的奖赏特性。为了测试 RGS12 缺失后观察到的反应变化是否是由于多巴胺转运体表达和/或功能的变化引起的,我们从野生型和 RGS12 缺失小鼠的大脑中制备了粗制膜,并测量了多巴胺转运体选择性 [H]WIN 35428 结合,结果显示 RGS12 缺失小鼠的腹侧纹状体而非背侧纹状体中的多巴胺转运体水平增加。为了研究多巴胺转运体的功能,我们制备了纹状体突触小体并测量了 [H]多巴胺摄取。与 [H]WIN 35428 结合增加一致,发现 RGS12 缺失的腹侧纹状体突触小体中的多巴胺转运体特异性 [H]多巴胺摄取增加。用另一种独立的 RGS12 缺失小鼠品系再现了安非他命诱导的运动活性降低和 [H]WIN 35428 结合增加。因此,我们提出 RGS12 调节腹侧纹状体中的多巴胺转运体表达和功能,影响安非他命和可卡因诱导的多巴胺水平升高,从而引发急性过度运动反应。